Diagnostics

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

As Sera Prognostics preps its year-end report, investors watch to see if its groundbreaking preterm birth test can deliver financial health.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

A massive $125M investment empowers five international teams to pursue radical ideas, from cancer-proof people to self-destructing tumors.

A nonprofit's initiative just gave its 4 millionth free vaccine, revealing a strategic model that tackles pet health crises and opens doors to lifelong care.

A new partnership integrates advanced AI for brain lesion tracking into a global imaging network, promising safer Alzheimer's treatments and faster diagnostics.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

With four new partners and a zero-markup model, Harrison.ai's Open Platform aims to democratize access to powerful medical AI tools for providers globally.

As a deadly superbug spreads, BioVersys's BV100 enters late-stage trials, backed by promising data and a novel scientific approach to combat resistance.

Jordan Faeth of Netflix's 'Love is Blind' is using his fame to tackle a silent epidemic affecting millions, destigmatizing sleep apnea one breath at a time.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

A new exclusive partnership between lens giant ZEISS and MEC aims to arm independent practices with advanced tech and operational might. But what does it mean?

Landmark recommendations give universities a legal and practical roadmap to support students with celiac disease, reshaping disability access on campus.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

A new report from the nation's largest eye care provider boasts stellar results. We dig into the data, the industry trends, and what it means for patients.

PathAI's PathAssist Derm receives FDA Breakthrough designation, promising to enhance accuracy and speed in diagnosing the most common cancer in the U.S.

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

Amid a strategic overhaul, Hepion Pharmaceuticals is licensing a novel RNA-based liquid biopsy, aiming to transform early liver cancer detection.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.